TrialAnnals of oncology : official journal of the European Society for Medical Oncology2023

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.

K Jhaveri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.